IRVING, TX–(Marketwire – August 2, 2010) – VHA Inc., the national health care network, will showcase its VHA SupplyLYNX™ portal and its array of analytics offerings at the annual meeting of the Association for Healthcare Resource & Materials Management Conference on August 1-4, in Denver.

VHA SupplyLYNX offers hospitals the ability to analyze every aspect of their purchasing activities for both products and services and gives them the data they need to accelerate the pace at which hospitals can reduce spending and maximize contract savings.

“VHA SupplyLYNX enables hospitals to fully optimize data throughout the organization and delivers unparalleled insight into the hospital’s performance,” said Scott Downing, executive vice president, Supply Chain Management at VHA. “Cost reduction is a daily focus and is essential to offset anticipated cuts in Medicare reimbursement that will decrease hospital revenues and potentially stifle the bottom line.”

In addition to the recently introduced VHA SupplyLYNX Web portal, attendees can participate in demonstrations of VHA PriceLYNX™ 2.0, the industry’s leading price benchmarking service. VHA PriceLYNX provides benchmarking analysis that arms decision makers with factual information that enables the organization to view long- and short-term market trends and respond to immediate price fluctuations. Ultimately, this information better equips the purchasing team during vendor negotiations. From January 2009 through June 2010, members using VHA PriceLYNX have identified an average savings of $4 million per quarter. 

AHRMM marks the public debut of VHA PriceLYNX mobile. VHA anticipates that mobile access via devices such as smart phones will give hospital personnel the opportunity to make faster decisions when it comes to switching products or accessing lower pricing on the products they already purchase. VHA recently launched its VHA SupplyLYNX mobile platform, built in conjunction with McLean, Va.-based MicroStrategy, to provide mobile access to its suite of analytical products and services. 

“Beginning with our leadership around data standards and e-commerce in 2001, VHA has led other analytics competitors by providing accurate, timely and actionable supply chain information to members, backed by the largest data set in health care,” continued Downing. “What sets us apart is our core belief in price transparency, a data warehouse that provides superior accuracy and a categorization methodology that ensures quality reporting every time.”

About VHA — VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves more than 1,400 hospitals and more than 28,000+ non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

GILBERT, AZ–(Marketwire – August 2, 2010) – As your boss reminds you that this is your third sick day in two months due to your “back pain excuse,” you hang up the phone frustrated. You aren’t playing hooky. You’d honestly rather be at work than flat on your back in pain. But taking painkillers makes it hard for you to function properly — and it merely masks the pain, instead of solving the problem. If only there was a solution that didn’t involve a knife and more time off work.

“When I treat patients with the one-two punch of spinal decompression and deep tissue laser therapy, they are able to return to their favorite activities, such as gardening, walking, dancing and tennis,” says Brian Self, D.C., a chiropractor with Arizona Pain & Wellness Centers. “And with 6.5 million people stuck in bed each day because of back pain, literally millions could benefit from this affordable, effective, permanent pain relief. While both procedures require multiple visits, most patients feel relief from their pain after their first few sessions.”

Spinal decompression is a revolutionary new technology that treats the symptoms of disc herniations, disc degeneration, sciatica and low back and neck pain. Patients simply lie on their backs while a specialized belt is placed comfortably around their waist. An advanced computer system is then set to focus on each patient’s specific problem area. As disc bulges or herniations are drawn in, or as the discs begin to regenerate, pressure is taken off the nerves and surrounding structures relieving the patient of pain and inflammation. In fact, Dr. Self says that the spinal decompression treatments are so gentle; he’s had patients become so relaxed, they fall asleep during it.

Most patients undergoing spinal decompression will also receive deep tissue laser therapy; because Dr. Self has found that these two treatments work best in tandem. “Our deep tissue laser works by flooding the tissues with photons, energizing the damaged cells and increasing circulation to the painful area,” he says. “This produces a cascade of healing responses in your body, reducing inflammation, thereby reducing or even eliminating your pain. There are no known side effects, it’s noninvasive and nonsurgical — and treatment simply feels like a deep, gentle warmth.”

To put an end to your neck and back pain without medications, injections or surgery, visit www.arizonapainandwellness.com

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 30, 2010) –  Increased demand for testing, new technologies and emerging markets have trumped the economic situation in the world in vitro diagnostics (IVD) market, according to the seventh edition of Kalorama Information’s biennial report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” The healthcare market research publisher reported a $44.3 billion market in 2009, and expects growth to be at a rate of six percent for the next five years. 

According to Kalorama the market has already weathered price declines and as a result developed innovative technologies and approaches. This has dulled the impact of a recession which has hurt other industries. Digital pathology, multiplex assays, automation and test service commercialization represent areas where the industry has developed new approaches. The market changes described in the report were on display at the American Association for Clinical Chemistry (AACC) convention in Anaheim, CA this week.

“The convention reflected what we’ve said in the report; that despite economic hard times, the IVD industry is on an upswing,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and author of the study. “A number of world events bode well for the future of testing.”

Trends such as the use of biomarkers and molecular approaches to testing have only increased since the last edition of the report. Consolidation has been a factor in an industry that is dominated by Roche, Siemens, and Abbott. The report notes that 72 percent of the revenue in 2009 was earned by just 18 companies. This hasn’t stopped scores of new companies with unique approaches from competing in diagnostics, according to Kalorama.

The report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition,” has more information on segment market sizes, forecasts, company analyses, and test product development. The report can be found at Kalorama Information at: http://www.kaloramainformation.com/redirect.asp?progid=79398&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

OAKBROOK TERRACE, IL–(Marketwire – July 30, 2010) –  Each year, millions of people — from elderly nursing home residents to hospitalized children to women who have just given birth — are injured by falls in health care facilities and homes. The Joint Commission today launched a national campaign to help Americans reduce the risk of falling.

The new education campaign, which is part of The Joint Commission’s award-winning Speak Up™ program, recognizes that falls are a serious problem. Statistics from the Centers for Disease Control and Prevention (CDC) show that falls are the second leading cause of injury-related deaths for people ages 65 and older, and are the most common cause of injuries and hospital admissions among the elderly. (Source: CDC, NCHS. Mortality Data Tapes. Hyattsville, MD: the Center, 1998.) Reducing injuries, disabilities and deaths from falls has even been included as part of the Healthy People 2010 program. The national Healthy People 2010 objectives from the U.S. Department of Health and Human Services identify the most significant preventable threats to health and establish national goals to reduce these threats.

“Falls can cause serious to life-threatening injuries; however, there are steps people can take at home or in a health care facility to reduce their risk of falling. We want people to be aware of these simple yet important precautions and avoid preventable injuries,” says Mark R. Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission.

The new Speak Up™ campaign offers tips and actions that will help people reduce the risk of falling, whether at home or in a medical facility. Among the topics are:

• Taking care of your health — this includes exercise to improve strength and balance, staying hydrated, having an eye exam regularly and talking to your doctor about any side effects from medications that might cause drowsiness or confusion.
• Taking extra precautions — simple actions such as turning on the lights when entering a room, keeping walkways clear, using handrails on stairs, and wearing proper shoes can make a difference.
• Making small changes to your home — using motion sensors or timers for lights, placing nightlights in bedrooms and bathrooms, removing throw rugs, and applying non-slip decals on stairs and in bathtubs to reduce the risk of falls. Home care agencies, personal care and support agencies, or community programs may be available to help you accomplish these tasks if you are older or disabled.
• Taking extra precautions in the hospital or nursing home, for example, people in health care facilities should use the call button to ask for help to get out of bed or go to the bathroom, wear non-slip socks, lower the height of the bed and bed rails, and tell the nurse or doctor if medicine is making you feel dizzy or sick.

The framework of the Speak Up™ program urges patients to:

• Speak up if you have questions or concerns, and if you don’t understand, ask again. It’s your body and you have a right to know.
• Pay attention to the care you are receiving. Make sure you’re getting the right treatments by the right health care professionals. Don’t assume anything.
• Educate yourself about your diagnosis, the medical tests you are undergoing, and your treatment plan.
• Ask a trusted family member or friend to be your advocate.
• Know what medications you take and why you take them. Medication errors are the most common health care errors.
• Use a hospital, clinic, surgery center, or other type of health care organization that has undergone a rigorous on-site evaluation against established state-of-the-art quality and safety standards, such as that provided by The Joint Commission.
• Participate in all decisions about your treatment. You are the center of the health care team.

Speak Up™ brochures also are available on preventing errors in medical care for children, finding pain relief, understanding caregivers, understanding medical tests, recovering after leaving the hospital, preventing medication mistakes, preventing infections, preparing to become a living organ donor, avoiding wrong site surgery and preventing errors in care. Brochures can be found at http://www.jointcommission.org/PatientSafety/SpeakUp/. All of the Speak Up™ brochures are available in an easy-to-read format and in Spanish.

Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission evaluates and accredits more than 17,000 health care organizations and programs in the United States, including more than 9,500 hospitals and home care organizations, and more than 6,300 other health care organizations that provide long term care, behavioral health care, laboratory and ambulatory care services. In addition, The Joint Commission also provides certification of more than 1,000 disease-specific care programs, primary stroke centers, and health care staffing services. An independent, not-for-profit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

To view this release in a media-rich format, go to: http://www.pwrnewmedia.com/2010/jointcommission_00728_Fall_Prevention/index.html

Click here to see all recent news from this company

HOUSTON, TX–(Marketwire – July 30, 2010) –  Bederra Corporation (PINKSHEETS: BEDA) management announced that the company has attained Pinksheet Current Information status on otcmarkets.com. Management had previously announced its intention to satisfy the “Alternative Reporting Standard” of public transparency in the company’s efforts to further investor relations and voluntarily make adequate and current information publicly available.

Management also noted that it remains currently in discussions with several potential acquisition candidates both in the medical area and outside this market. While the company remains dedicated to further growth in the medical services industry, management had recently announced its decision to explore diversification options in the interest of shareholders until further information regarding the overall direction of the recently passed healthcare legislation is announced. 

About Bederra Corp.
http://www.bederra.com
Bederra Corporation provides multiple modality diagnostic medical services to the greater Houston area and the world famous Texas Medical Center. The Company’s business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 30, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today reported its financial results
for the six months ended June 30, 2010 and provided a business update on
its activities.

Michele Garufi, Chairman and CEO of NicOx, declared: “This has been both an
active and a challenging first half for NicOx, as we worked with regulators
in the United States and Europe on the marketing applications for
naproxcinod. We will collaborate closely with both regulatory authorities
in the coming months. We will also focus on securing potential licensing
agreements for naproxcinod in Europe and the rest of the world, ensuring
the continued success of our existing partnerships and prioritizing our
research programs. We will continue to manage our cash resources in the
most cost-effective manner to ensure the future growth of the Company
whilst also pursuing appropriate in-licensing and M&A opportunities.”

Key events of the first six months of 2010:

– NicOx and Bausch + Lomb signed a Worldwide Licensing Agreement for the
glaucoma candidate NCX 116

– The European Medicines Agency (EMA) validated the Marketing Authorization
Application (MAA) for naproxcinod

– Joint Advisory Committee of the U.S. Food and Drug Administration (FDA)
voted that they did not have sufficient evidence to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis

– Additional clinical data for naproxcinod and preclinical results for NCX
434 and NCX 1236, two of the Company’s nitric oxide (NO)-donating New
Molecular Entities, were presented at scientific and medical conferences

– NicOx and TOPIGEN Pharmaceuticals Inc. mutually terminated their
collaboration for TPI 1020 as a result of the acquisition of TOPIGEN

Post reporting period:

– On July 22, 2010, NicOx announced the receipt of a Complete Response
Letter from the U.S. Food and Drug Administration (FDA), stating that it
could not approve the New Drug Application (NDA) for naproxcinod. NicOx
plans on discussing the Complete Response Letter and potential next steps
with the FDA, as early as possible.

Eric Castaldi, Chief Financial Officer of NicOx, declared: “NicOx has a
strong cash position, with no long-term debt and cash and cash equivalents
totaling ?128.4 million at the end of June 2010. We will continue to
ensure careful conservation of our funds.”

Financial summary for the first half of 2010:

Revenues for the first half of 2010 were ?7.4 million, compared to
?1.1 million during the same period in 2009. These revenues correspond
to the initial license payment received from Bausch + Lomb in the first
quarter of the year, as per the agreement signed in March 2010.

For the first six months of 2010, operating expenses were ?36.4
million, compared to ?32.7 million for the same period in 2009. These
expenses correspond principally to personnel costs related to the
regulatory processes for naproxcinod both in the United States and in
Europe, investments in naproxcinod’s supply chain and costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA.

NicOx recorded a total net loss for the period of ?27.5 million for
the first six months of 2010, compared to a corresponding net loss of
?27.2 million for the same period in 2009. On June 30, 2010, NicOx had
cash and cash equivalents of ?128.4 million, compared to ?148.3
million on December 31, 2009.

Review of the first six months of 2010:

Signature of a Worldwide Licensing Agreement with Bausch + Lomb

In March 2010, NicOx and Bausch + Lomb signed a Worldwide Licensing
Agreement granting Bausch + Lomb exclusive rights to develop and
commercialize NCX 116, an NO-donating prostaglandin F2-alpha analog for the
potential treatment of glaucoma and ocular hypertension. Both companies
have already held an initial meeting to agree on the next steps for the
development of NCX 116. Under the terms of this agreement, NicOx received
an initial license payment of $10 million and stands to receive potential
milestones totaling $169.5 million, as well as tiered double-digit
royalties on the sales of NCX 116.

Regulatory status of naproxcinod in the United States

A Joint Advisory Committee of the FDA, including the Arthritis Drugs
Advisory Committee and the Drug Safety and Risk Management Advisory
Committee, voted by 16 to 1 with 1 abstention on May 12, 2010 that they did
not have sufficient evidence at that time to support the approval of
naproxcinod for the relief of the signs and symptoms of osteoarthritis.

On July 22, 2010, NicOx announced the receipt of a Complete Response Letter
from the U.S. Food and Drug Administration (FDA) related to the New Drug
Application (NDA) for naproxcinod. The FDA informed NicOx that its review
of the NDA was complete and that it did not approve the naproxcinod
application. The FDA recommended conducting one or more long-term
controlled studies to assess the cardiovascular and gastrointestinal safety
of naproxcinod. Additional studies to demonstrate a clinically meaningful
therapeutic benefit attributable to the nitric oxide donation were also
recommended. No clinical efficacy studies were requested. NicOx plans to
discuss the Complete Response Letter and potential next steps as early as
possible with the FDA.

Regulatory status of naproxcinod in Europe

In January 2010, the European Medicines Agency (EMA) validated the
Marketing Authorization Application (MAA) for naproxcinod, which was
submitted through the centralized procedure in December 2009. NicOx is
seeking approval for an indication for the relief of the signs and symptoms
of primary osteoarthritis. The Medicinal Products for Human Use (CHMP)
opinion is expected by mid-2011, the exact timing depending on the
interactions needed with the health authorities in the last phase of the
review process.

Presentation of scientific results for naproxcinod

Detailed results from the 301 study were published in the May issue of
Osteoarthritis and Cartilage. Additional clinical data for naproxcinod were
presented in May at the American Society of Hypertension Annual Scientific
Meeting and Exposition in New York and in June at the European Meeting on
Hypertension in Olso and the Annual European Congress of Rheumatology in
Rome.

Presentation of promising preclinical results in international conferences

Preclinical results obtained with two of NicOx’s NO-donating New Molecular
Entities (NMEs) were presented in congresses in the first half of 2010. In
May, preclinical findings obtained with NCX 1236, a lead compound for the
potential treatment of Neuropathic Pain, were presented at the
International Congress on Neuropathic Pain in Athens. Preclinical results
for NCX 434, a potential preclinical candidate in Diabetic Macular Edema
(DME), were presented in May at the Ocular Diseases & Drug Discovery
conference in Boston and in June at the Retina International World Congress
in Stresa.

Review of the consolidated financial results for the six months ended June
30, 2010 and 2009:

Revenues

NicOx’s revenues totaled ?7.4 million for the six months ended June
30, 2010 compared to ?1.1 million for the six months ended June 30,
2009.

This significant increase results from the recognition as revenues during
the first quarter of 2010 of ?7.4 million corresponding to the initial
license payment received from Bausch + Lomb following the signature of a
licensing agreement in March 2010 that granted Bausch + Lomb exclusive
worldwide rights to develop and commercialize NCX 116. This amount has been
immediately recognized in revenues because the Company will not have
continuing involvement in the future development of the compound which is
subject of this collaboration agreement. No revenues have been recorded in
the second quarter of 2010.

Operating expenses

For the six months ended June 30, 2010, operating expenses totaled
?36.4 million, compared to ?32.7 million for the six months ended
June 30, 2009, of which, 74% was attributable to research and development
expenses and 26% attributable to selling and administrative expenses in the
first semester of 2010, compared to 77% and 23% respectively in the first
semester of 2009.

Research and development expenses were ?26.9 million during the first
semester of 2010, compared to ?25.1 million during the first semester
of 2009 (including ?0.1 million allocated to cost of sales in 2009
corresponding to the expenses incurred by NicOx in performing research
activities under the contract signed with Pfizer). In the first semester of
2010, research and development expenses correspond principally to personnel
expenses related to the activities performed in relation with the
naproxcinod New Drug Application and Marketing Authorization Application
submitted respectively in the US and in Europe and to investment expenses
in dedicated manufacturing facilities of its active ingredient supplier DSM
in order to increase the naproxcinod supply chain capacity and flexibility.
Following the decision in July 2010 of the FDA not to approve the marketing
application for naproxcinod in the US, indemnities in an amount of
?6.9 million have been booked as research and development expenses in
the accounts as of June 30, 2010, to be paid to suppliers involved in the
manufacturing of naproxcinod for the anticipated cancellation of purchase
orders. The Company employed 79 people in research and development on June
30, 2010, compared to 93 people at the same date in 2009.

General and administrative expenses were ?3.2 million in the first
semesters of 2010 and 2009 and include personnel expenses in administrative
and financial functions, as well as the remuneration of corporate officers,
including stock option, free share and warrant attributions. Selling and
corporate development expenses totaled ?6.2 million during the first
six months ended June 30, 2010 compared to ?4.4 million during the
same period in 2009 and correspond to market research and analysis
activities for naproxcinod, as well as the business development and
communication activities of the Company. The Company employed 48 people in
its selling, general and administrative departments on June 30, 2010,
compared to 39 people on June 30, 2009.

Other income

Other income totaled ?1.6 million during the first semester of 2010
compared to ?3.1 million in the first semester of 2009. Other income
corresponds mainly to the operational subsidies from the research tax
credits in France and in Italy.

Operating result

The operating loss amounted to ?27.4 million in the six months ended
June 30, 2010, compared to ?28.5 million in the same period in 2009.

Other results

Net financial income totaled ?0.1 million during the first semester of
2010, compared to ?1.3 million during the first semester of 2009, and
represents mainly the returns on the financial investments of the Company’s
cash, cash equivalents.

The income tax expense incurred by NicOx during the first six months of
2010 relates to tax from its US and Italian subsidiaries and totaled
?0.3 million, compared to ?0.1 million during the same period in
2009.

Total net loss of the period

The total net loss for the period was ?27.5 million on June 30, 2010,
compared to ?27.2 million on June 30, 2009. Notwithstanding the strong
increase of the revenues recognized in the first six months of 2010
following the initial license payment received from Bausch + Lomb, the
total net loss on June 30, 2010 remains at the same level as last year due
to the impact of the anticipated cancellation of manufacturing and pre-
commercial activities related to naproxcinod following the decision of the
FDA not to approve the application of the product in the United States.

Consolidated statement of financial position

The indebtedness incurred by NicOx is mainly short-term operating debt. On
June 30, 2010, the Company’s current liabilities totaled ?16.6
million, including ?12.0 million in accounts payable to suppliers and
external collaborators (including ?5.9 million with respect to the
cancellation of orders of naproxcinod active drug substance), ?2.5
million in accrued compensation for employees, ?1.9 million in other
contingencies and liabilities (corresponding to the costs related to the
anticipated cancellation of certain manufacturing and pre-commercial
activities following the decision of the FDA) and ?0.2 million for
other liabilities.

The Company’s cash and cash equivalents were ?128.4 million on June
30, 2010, compared to ?148.3 million on December 31, 2009, and
?76.8 million on June 30, 2009. In late 2009, the Company completed a
two step capital increase and received a total of ?94.6 million
corresponding to the net proceeds of the following operations: ?29.4
million from a private placement of shares to institutional investors
completed on November 23, 2009, and ?65.2 million from a rights issue
completed on December 23, 2009.

NicOx will continue to pursue the European regulatory process for
naproxcinod and follow-up with the FDA after the Complete Response Letter.
NicOx will actively seek to enter into partnerships for naproxcinod. The
Company’s cash position is strong and NicOx is taking all necessary steps
to preserve it.

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website (www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements. For a discussion of
risks and uncertainties which could cause actual results, financial
condition, performance or achievements of NicOx S.A. to differ from those
contained in the forward-looking statements, please refer to the Risk
Factors (“Facteurs de Risque”) section of the Document de Reference filed
with the AMF, which is available on the AMF website (http://www.amf-
france.org) or on NicOx S.A.’s website (http://www.nicox.com).

+-------------------------+-+--------------------+-+---------+
|                         | |For the period ended| |         |
|                         | |June 30,            | |         |
+-------------------------+-+--------------------+-+---------+
|                         | |2010                | |    2009 |
+-------------------------+-+--------------------+-+---------+
|                         | |(in thousands of EUR| |         |
|                         | |except for per share| |         |
|                         | |data)               | |         |
+-------------------------+-+--------------------+-+---------+
|Revenues                 | |7,423               | |   1,119 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Cost of sales            | |-                   | |    (75) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Research and development | |(26,924)            | |(25,031) |
|expenses                 | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Administrative expenses  | |(3,214)             | | (3,234) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Selling expenses         | |(6,241)             | | (4,403) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other income             | |1,600               | |   3,130 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Operating loss           | |(27,356)            | |(28,494) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance income           | |183                 | |   1 388 |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Finance expense          | |(70)                | |    (54) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Loss before income tax   | |(27,243)            | |(27,160) |
|                         | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Income tax expense       | |(257)               | |    (77) |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Net loss of the          | |(27,500)            | |(27,237) |
|period                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Exchange differences on  | |(38)                | |     (1) |
|translation of foreign   | |                    | |         |
|operations               | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Other comprehensive      | |(38)                | |     (1) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Total comprehensive      | |(27,538)            | |(27,238) |
|income (loss) for the    | |                    | |         |
|period, net of tax       | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Attributable to:         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Equity holders of the  | |(27,538)            | |(27,238) |
|parent                   | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|- Non-controlling        | |-                   | |       - |
|interests                | |                    | |         |
|                         | |                    | |         |
|                         | |                    | |         |
+-------------------------+-+--------------------+-+---------+
|Basic and diluted loss   | |(0.38)              | |  (0.57) |
|per share attributable to| |                    | |         |
|equity holders of the    | |                    | |         |
|parent                   | |                    | |         |
+-------------------------+-+--------------------+-+---------+

+----------------------+--------------------+-+------------------+--------+
|                      |   June 30, 2010    | |December 31, 2009 |        |
+----------------------+--------------------+-+------------------+--------+
|                      |(in thousands       | |                  |        |
|                      | of EUR)            | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|ASSETS                |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current assets    |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Property, plant &     |              2,782 | |                  |  2,772 |
|equipment             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Intangible assets     |                794 | |                  |    797 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |                936 | |                  |    477 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other financial assets|                267 | |                  |    238 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                  - | |                  |    156 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,779 | |                  |  4,440 |
|assets                |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current assets        |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Government subsidies  |              3,263 | |                  |  2,597 |
|receivable            |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other current assets  |                988 | |                  |  1,329 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Prepaid expenses      |              1,213 | |                  |    784 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Cash and cash         |            128,448 | |                  |148,275 |
|equivalents           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current assets  |            133,912 | |                  |152,985 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL ASSETS          |            138,691 | |                  |157,425 |
+----------------------+--------------------+-+------------------+--------+
|EQUITY AND LIABILITIES|                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Common shares         |             14,505 | |                  | 14,434 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other reserves        |            103,046 | |                  |128,444 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-controlling       |                  - | |                  |      - |
|interests             |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total Equity          |            117,551 | |                  |142,878 |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Non-current           |                    | |                  |        |
|liabilities           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              4,369 | |                  |  4,069 |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Deferred income tax   |                 98 | |                  |     91 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 44 | |                  |      6 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total non-current     |              4,511 | |                  |  4,166 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current liabilities   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other contingencies   |              1,890 | |                  |      - |
|and liabilities       |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Finance lease         |                 18 | |                  |      7 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Trade payables        |             12,034 | |                  |  6,136 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Current income tax    |                  - | |                  |     19 |
|payable               |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Social security and   |              2,504 | |                  |  3,909 |
|other taxes           |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Other liabilities     |                183 | |                  |    310 |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Total current         |             16,629 | |                  | 10,381 |
|liabilities           |                    | |                  |        |
|                      |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|TOTAL EQUITY AND      |            138,691 | |                  |157,425 |
|LIABILITIES           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|NicOx S.A.,           |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
|Les Taissounières-Bât |                    | |                  |        |
|HB4 - 1681 route des  |                    | |                  |        |
|Dolines - BP313, 06906|                    | |                  |        |
|Sophia Antipolis cedex|                    | |                  |        |
|France.               |                    | |                  |        |
|Tel.                  |                    | |                  |        |
|+33 (0)4 9724 53 00   |                    | |                  |        |
|Fax                   |                    | |                  |        |
|+33 (0)497 24 53 99   |                    | |                  |        |
+----------------------+--------------------+-+------------------+--------+
+----------------------+--------------------+-+------------------+--------+

This information is provided by HUGIN

SAN DIEGO, CA–(Marketwire – July 29, 2010) –  Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper identifying a molecule found on the company’s lead product, the universal donor Endometrial Regenerative Cell (ERC), as a key component of cellular escape from immune attack. The study, titled “Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59,” was published in the journal Xenotransplantation as a collaboration between Medistem and the Institute of Organ Transplantation, Tongji Hospital, in Wuhan, China.

The study found that CD59, a molecule made by ERC, plays an important role in protecting cells from immune rejection when placed in contact with immune components from another species. The ERC is a mesenchymal-like stem cell that Medistem discovered in 2007 capable of generating heart, lung, brain, muscle, blood vessel, pancreas, liver, fat and bone tissue. The original description of this cell, which won the “Publication of the Year Award” may be found at http://www.translational-medicine.com/content/pdf/1479-5876-5-57.pdf.

“One of the fundamental aspects of Medistem’s lead product, the Endometrial Regenerative Cell (ERC), is its ability to function without the need for tissue matching. In other words, the ERC stem cells act as universal donors. We have previously published that human ERC are effective in treating mice having a condition that resembles critical limb ischemia (see paper http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf). We now believe that expression of the molecule CD59 on ERC may be one of the mechanisms by which these human cells can be used not only as a universal donor for humans, but also for the treatment of numerous diseases across a variety of animal species,” said Thomas Ichim, CEO of Medistem.

Medistem has filed an IND with the FDA for treatment of critical limb ischemia (severe obstruction of the arteries that leads to decreased blood flow to the extremities) with ERC. Currently the company is in the process of completing additional experiments requested by the FDA before clinical trials can commence. Through physician-initiated compassionate use mechanisms Medistem has already published on human use of ERC in treatment of heart failure, Duchenne Muscular Dystrophy, and multiple sclerosis. A recent peer-reviewed paper describing ERC in treatment of heart failure may be found at http://www.intarchmed.com/content/pdf/1755-7682-3-5.pdf.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

MADISON, WI–(Marketwire – July 29, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), producer of the Hi*Art® treatment system and other products for
advanced radiation therapy, today released financial results for the second
quarter ended June 30, 2010.

Second Quarter Results

Second quarter 2010 revenue was $47.6 million, an increase of 16% from
$41.1 million in the second quarter of 2009. Revenue from product sales
was $34.2 million in the second quarter of 2010, up 12% compared to the
same quarter last year, and revenue from service and other was $13.4
million in the second quarter of 2010, up 27% compared to the same quarter
last year. The company reported a second quarter 2010 loss from operations
of $8.4 million, a 14% decrease from the $9.7 million loss from operations
for the same period last year.

The company incurred a net loss attributable to shareholders of $6.9
million, or $0.13 per share, for the second quarter of 2010, compared to a
net loss of $7.1 million, or $0.14 per share, for the second quarter of
2009.

As of June 30, 2010, the company had $145.7 million of cash, cash
equivalents and short-term investments, representing a $3.0 million
decrease from March 31, 2010, and minimal debt. During the quarter, there
were no borrowings against the company’s credit facility.

As of June 30, 2010, the company had a revenue backlog of $139.2 million, a
4% increase from the $134.2 million backlog as of March 31, 2010. The
backlog includes $42.5 million of equipment orders received during the
second quarter of 2010. One order was removed from backlog during the
second quarter due to uncertainty surrounding the project schedule.
Backlog includes only firm orders that the company believes are likely to
ship within the next two years. Backlog does not include any revenue from
service contracts, which represents a growing portion of the company’s
overall revenue.

“Our second quarter financial results were in line with our internal
expectations and represent a solid improvement over the same period last
year,” said Fred Robertson, TomoTherapy’s CEO. “In addition, we are
pleased with the 13% increase in revenue from the first quarter of 2010 and
the $5.0 million net increase to our backlog since March 31, 2010.
Specifically, we realized a rise in new orders, which we believe reflects
the strength of our new product offerings as well as enhanced global sales
and marketing efforts. On the service side, revenue increased
significantly compared to the same period last year, due to continued
growth in the number of service contracts, and we again achieved strong
customer service rankings. We continue to take steps to enhance our
financial performance and drive toward profitability while still investing
in key product development initiatives. Importantly, our capital position
remained strong in the quarter despite the continuing challenges in the
global economy.”

Six-Month Results

For the six months ended June 30, 2010, revenue was $89.7 million, a 25%
increase from $71.7 million for the six months ended June 30, 2009.
Revenue from product sales was $63.5 million in the first half of 2010, up
23% compared to the first half of 2009, and revenue from service and other
was $26.2 million in the first half of 2010, up 31% compared to the first
half of 2009.

The company reported a year-to-date 2010 loss from operations of $14.4
million, a 39% decrease from the loss from operations of $23.7 million
during the first six months of 2009. The company incurred a net loss
attributable to shareholders of $11.6 million, or $0.22 per share, for the
six months ended June 30, 2010, compared to a net loss attributable to
shareholders of $20.1 million, or $0.40 per share, for the same period last
year.

During the first half of 2010, the company’s cash, cash equivalents and
short-term investments decreased by $8.7 million. The company’s backlog
increased by $3.4 million during the first half of 2010, from $135.8 as of
December 31, 2009 to $139.2 million as of June 30, 2010.

Outlook

The company reaffirms its revenue and earnings guidance for full-year 2010.
Management still expects 2010 revenue to be comparable to 2009 revenue of
$160 million to $180 million, with a net loss attributable to shareholders
in the range of $0.65 to $0.85 per share. Consistent with prior years,
management is not providing specific quarterly guidance. However, similar
to 2009, management anticipates that the timing of expected customer
deliveries will result in 2010 second half revenues being heavily weighted
toward the fourth quarter.

Robertson concluded, “Given our second quarter performance and expectations
for the balance of the year, we remain on track to deliver results in line
with our previously announced guidance. While there is still uncertainty
with respect to macro conditions, particularly in Europe, we are encouraged
by recent performance in North America and Asia. We also continue to make
good progress on several key initiatives, including diversifying our
product line-up and expanding our business both in North America and other
global markets. With significant interest in our TomoDirect™ and
TomoHD™ offerings, entry into new markets, and greater access to many
hospitals through new strategic Group Purchasing Organization agreements,
we believe TomoTherapy is well positioned to capitalize on the substantial
opportunity in the growing global radiation therapy market.”

Investor Conference Call

TomoTherapy will conduct a conference call regarding its second quarter
2010 results at 5:00 p.m. EDT today, July 29, 2010 (4:00 p.m. CDT). To
hear a live Webcast or replay of the call, visit the Investor Relations page at TomoTherapy.com, where it will
be archived for two weeks. To access the call via telephone, dial
1-800-260-8140 from inside the United States or
1-617-614-3672 from outside the United States, and enter pass code
35309628. The replay can be accessed by dialing 1-888-286-8010 from inside
the United States or 1-617-801-6888 from outside the United States and
entering pass code 64325104. The telephone replay will be available
through 11:59 p.m. CDT on August 5, 2010.

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation
therapy solutions that can be used to efficiently treat a wide variety of
cancers, from the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with speed
and precision while reducing radiation exposure to surrounding healthy
tissue. TomoTherapy’s suite of solutions includes its flagship Hi*Art®
treatment system, which has been used to deliver more than three million
CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment
fractions; the TomoHD™ treatment system, designed to enable cancer centers
to treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to improve
access and availability of state-of-the-art cancer care. TomoTherapy’s
stock is traded on the NASDAQ Global Select Market under the symbol “TOMO.”
To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements
concerning market acceptance of the company’s technology; growth drivers;
the company’s orders, revenue, backlog or earnings growth; future financial
results and any statements using the terms “should,” “believe,” “outlook,”
“expect,” “anticipate” or similar statements are forward-looking statements
that involve risks and uncertainties that could cause the company’s actual
results to differ materially from those anticipated. Such risks and
uncertainties include: demand for the company’s products; impact of sales
cycles and competitive products and pricing; the effect of economic
conditions and currency exchange rates; the company’s ability to develop
and commercialize new products; its reliance on sole or limited-source
suppliers; its ability to increase gross margins; the company’s ability to
meet U.S. Food and Drug Administration (FDA) and other regulatory agency
product clearance and compliance requirements; the possibility that
material product liability claims could harm future revenue or require the
company to pay uninsured claims; the company’s ability to protect its
intellectual property; the impact of managed care initiatives, other health
care reforms and/or third-party reimbursement levels for cancer care;
potential loss of key distributors or key personnel; risk of interruptions
to the company’s operations due to terrorism, disease or other events
beyond the company’s control; and the other risks listed from time to time
in the company’s filings with the U.S. Securities and Exchange Commission,
which by this reference are incorporated herein. TomoTherapy assumes no
obligation to update or revise the forward-looking statements in this
release because of new information, future events or otherwise.

                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per share data)
                                (unaudited)



                                 Three Months Ended     Six Months Ended
                                      June 30,              June 30,
                                --------------------  --------------------
                                  2010       2009       2010       2009
                                ---------  ---------  ---------  ---------

Revenue:
 Product                        $  34,242  $  30,552  $  63,471  $  51,685
 Service and other                 13,388     10,528     26,239     20,018
                                ---------  ---------  ---------  ---------
  Total revenue                    47,630     41,080     89,710     71,703
                                ---------  ---------  ---------  ---------
Cost of revenue:
 Product                           17,354     14,253     30,139     25,998
 Service and other                 17,818     18,312     34,509     34,651
                                ---------  ---------  ---------  ---------
  Total cost of revenue            35,172     32,565     64,648     60,649
                                ---------  ---------  ---------  ---------
   Gross profit                    12,458      8,515     25,062     11,054
                                ---------  ---------  ---------  ---------
Operating expenses:
  Research and development          8,960      7,020     16,500     12,869
  Selling, general and
   administrative                  11,910     11,224     22,944     21,876
                                ---------  ---------  ---------  ---------
   Total operating expenses        20,870     18,244     39,444     34,745
                                ---------  ---------  ---------  ---------
Loss from operations               (8,412)    (9,729)   (14,382)   (23,691)
Other income (expense):
  Interest income                     416        695        947      1,392
  Interest expense                    (12)       (15)       (23)       (29)
  Other expense, net                 (578)      (107)    (1,026)      (363)
                                ---------  ---------  ---------  ---------
   Total other income (expense)      (174)       573       (102)     1,000
                                ---------  ---------  ---------  ---------
Loss before income tax and
 noncontrolling interests          (8,586)    (9,156)   (14,484)   (22,691)
  Income tax expense (benefit)         10       (318)       (34)      (418)
                                ---------  ---------  ---------  ---------
Net loss                           (8,596)    (8,838)   (14,450)   (22,273)
  Noncontrolling interests          1,673      1,715      2,849      2,151
                                ---------  ---------  ---------  ---------
Net loss attributable to
 shareholders                   $  (6,923) $  (7,123) $ (11,601) $ (20,122)
                                =========  =========  =========  =========

Weighted-average common shares
 outstanding -
 basic and diluted                 51,713     50,592     51,640     50,592
                                =========  =========  =========  =========

Loss per common share - basic
 and diluted                    $   (0.13) $   (0.14) $   (0.22) $   (0.40)
                                =========  =========  =========  =========





                TOMOTHERAPY INCORPORATED AND SUBSIDIARIES

                  CONDENSED CONSOLIDATED BALANCE SHEETS
                              (In thousands)
                                (unaudited)


                                                    June 30,   December 31,
                                                      2010         2009
                                                  ------------ ------------

                                  ASSETS
Cash and cash equivalents                         $     99,240 $     76,108
Short-term investments                                  46,434       78,225
Receivables, net                                        32,915       33,559
Inventories, net                                        53,204       47,669
Prepaid expenses and other current assets                5,507        3,633
                                                  ------------ ------------
 Total current assets                                  237,300      239,194
Property and equipment, net                             18,198       18,628
Other non-current assets, net                           10,588       12,429
                                                  ------------ ------------
 TOTAL ASSETS                                     $    266,086 $    270,251
                                                  ============ ============

                           LIABILITIES AND EQUITY
Accounts payable                                  $     11,896 $      6,269
Accrued expenses                                        20,273       19,588
Accrued warranty                                         3,776        4,173
Deferred revenue                                        31,506       34,145
Customer deposits                                       11,145       13,266
                                                  ------------ ------------
 Total current liabilities                              78,596       77,441
Other non-current liabilities                            4,404        5,475
                                                  ------------ ------------
 TOTAL LIABILITIES                                      83,000       82,916

Total shareholders' equity                             175,498      183,424
Noncontrolling interests                                 7,588        3,911
                                                  ------------ ------------
 TOTAL EQUITY                                          183,086      187,335

                                                  ------------ ------------
 TOTAL LIABILITIES AND EQUITY                     $    266,086 $    270,251
                                                  ============ ============

WAYNE, PA–(Marketwire – July 29, 2010) –  Clinical and Laboratory Standards Institute (CLSI) unveiled the release of StatisPro^™, its new method evaluation software package for the evaluation, verification, and validation of performance characteristics of laboratory test methods at the AACC/ASCLS Annual Meeting this week.

StatisPro software delivers a feature-rich tool designed to perform the statistical analysis necessary to meet regulatory and accreditation requirements. Hospitals, physician office laboratories, reference laboratories, and customer support departments of in vitro diagnostic manufacturers can benefit from using this new method evaluation software.

David Grenache, PhD, DABCC, FACB, Associate Professor, Department of Pathology, University of Utah, ARUP Laboratories, and beta-tester for StatisPro, says, “The benefits of StatisPro are its ease-of-use and intuitive interface. When validating a new method, replacing equipment, or preparing for accreditation or regulatory inspections, StatisPro makes advanced statistical analysis easier regardless of the size of the laboratory using it.”

Developed in conjunction with Analyse-it^®, StatisPro can produce reports on analytical accuracy, precision, linearity, limit of detection and quantitation, and reference intervals and is entirely based on the most up-to-date CLSI guidelines.

With StatisPro, laboratories can:

• Verify comparability of new methods and systems.
• Ensure comparable results across measuring systems.
• Establish reference intervals or transfer intervals between methods and laboratories.

James Huntington, Co-founder, Analyse-it^®, describes the importance of evaluating and verifying method performance, saying, “Laboratories must ensure method performance is as expected to meet regulatory or accreditation requirements. As the statistics necessary to determine method performance become more complex, software such as StatisPro is essential to ensure accurate, correct, determination of method performance.”

CLSI partnered with Analyse-it because of its excellent reputation and proven experience in creating statistically based software, as well as its similar culture and values to CLSI, explains Glen Fine, MS, MBA, CAE, CLSI Executive Vice President. “Since StatisPro is based on CLSI’s world-renowned best practices, it will inspire user confidence. This is the only software package available that streamlines implementation of CLSI’s latest method evaluation guidelines. StatisPro allows staff of laboratories of any size to produce advanced statistical calculations and display reports quickly and accurately in order to ensure the highest quality patient care,” says Fine. 

StatisPro is available directly from CLSI. For more information, please visit www.StatisPro.org or call 877.477.1888.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information visit the CLSI website at www.clsi.org or call 610.688.0100.

Analyse-it Software, Ltd. formed in 1997 to develop statistical analysis and charting software for Microsoft^® Excel^™, and built its flagship product, Analyse-it, through work with some of the world’s largest in vitro diagnostic companies. Now with more than 20,000 customers, Analyse-it is highly respected in the scientific and research community, and is used and cited in thousands of peer-reviewed published papers. For additional information, visit the Analyse-it website at www.analyse-it.com.

Click here to see all recent news from this company

KELLER, TX–(Marketwire – July 29, 2010) – In less time than it takes for a single lunch hour, employees can learn, for free, how to save a life through Cardiopulmonary Resuscitation (CPR). This because Dallas-based non-profit Mission CPR (www.MissionCPR.org) has launched its “Spend 45 Minutes, Save a Life” initiative offering workplace CPR awareness and basic skills training to area businesses and organizations completely free of charge. Mission CPR has launched this program as part of the American Heart Association’s overriding “CPR Anytime” campaign created to increase the incidence of bystander CPR by making training more accessible.

“A full 93.6 percent of sudden cardiac arrest victims die simply because the vast majority of those witnessing the arrest do not know how to perform CPR and are reluctant to even try,” says Jeff D. Hill, CEO of Mission CPR, whose own life was saved by CPR at age 3 and who has since saved a life using CPR through his work as an EMT. “Our organization aims to not only raise awareness about the vital importance of bystander CPR, but also actually save lives by providing local groups with basic, easily absorbed training in a convenient on-site workplace setting — at no cost to the employee, group member or organization.” 

“The session lasts only 45 minutes and very little time is needed to organize the presentation,” Hill underscores. “This program is an invaluable employee benefit that has nothing but upside for all involved — the company, employee, their families and the Dallas/Fort Worth community at large.”

At the age of 3, Hill’s own life was saved by bystander CPR. Left briefly unattended, he fell in a pool and drowned. Hill had no heartbeat and had stopped breathing completely. A visiting relative heard his mother screaming once she pulled Hill from the pool, and he jumped in to try to help. This relative had received CPR training years before and was unsure if he was “doing it right,” but he TRIED his best, revived Hill’s heartbeat, and kept him alive long enough until the EMS arrived to take over. This experience exemplifies why even the most basic understanding of CPR is important and how those skills can prove critical in an emergency situation.

Hill notes, “The reality is many people in distress that need CPR do not get the help because bystanders are not trained or are afraid to try. Indeed, in my prior work as a firefighter and EMT, most bystanders waited until we arrived to attempt CPR and, most often, it was too late. Even the most basic skills training can give someone the knowledge and confidence needed to attempt CPR until medical professionals arrive, and can mean the difference between life and death.”

In addition to its free “Spend 45 Minutes, Save a Life” training program, Mission CPR also offers interested and key employees full certification-based CPR and First Aid training at a reduced cost, with proceeds used to purchase additional American Heart Association CPR training kits to support and prolong the organization’s free training efforts. Mission CPR sessions are available for company meetings and conferences, “lunch and learns,” health fairs, benefits enrollment periods or any other time that best suits the business or organization. 

Interested parties may visit www.MissionCPR.org to learn more about Mission CPR’s free and reduced-fee certification programs. More information about the American Heart Association’s “CPR Anytime” campaign may be accessed online at http://www.trihealth.com/aus/srv/CPR_Anytime.aspx.

About Mission CPR
Based in Keller, Texas, Mission CPR is a non-profit organization dedicated to raising awareness about the vital importance of bystander CPR in both a local and nationwide effort to save lives. The organization provides free CPR awareness presentations and basic skills training, and reduced-cost CPR and First Aid certifications, to businesses and organizations of all types throughout the Dallas/Fort Worth region. Mission CPR is spearheaded by CPR recipient and survivor Jeff D. Hill who himself, as a former EMT, has saved the life of another using CPR. Contact Mission CPR at 817-509-0004 or [email protected], or learn more about the organization online at www.MissionCPR.org.

Click here to see all recent news from this company

HALIBURTON, ON–(Marketwire – July 29, 2010) – Patient News, a leading dental marketing company in the US and Canada, was recognized for its outstanding newsletter design and layout in the 22nd Annual Awards for Publication Excellence Competition (APEX). Judged by a panel of experienced writers and editors, the APEX 2010 awards are based on excellence in graphic design, editorial content, and the ability to achieve overall communications excellence. Despite an exceptionally intense competition with more than 3,700 entries, Patient News received an Award for Publication Excellency by Apex 2010 for Dr. Randy G. Fussell’s Fall 2009 dental marketing newsletter “Smile! Pass It on!”

“At Patient News we take great pride in our highly skilled editorial, design, and production teams who work together to create engaging, innovative, and personable patient marketing and potential patient marketing materials that speak directly to our clients’ targeted audience,” said Karen Galley, President of Patient News. “As the industry leader, our customized marketing methods are proven, reliable, professional, and diverse.”

Patient News offers a variety of innovative dental marketing products including dental email newsletters, patient newsletters, direct mail newsletters, dental postcards, patient referral cards and patient satisfaction surveys. All products are tailored to help achieve the specific goals of each client. With nearly 20 years of business and over 100 million newsletters and postcards later, Patient News provides health care specialists with measurably effective practice marketing. In addition to the APEX 2010 Award for Publication Excellency, Patient News has received a number of other awards, including Entrepreneur of the Year, Large Business of the Year, and the American Graphic Design Award.

Patient News has been producing dental marketing materials for almost 20 years in North America and the UK. For additional information on dental marketing from Patient News, call 800.667.0268 or visit www.patientnews.com. To read more on this topic, visit: http://www.patientnews.com/pressreleases/dental-marketing-excellency-award.html.

About Patient News:
 Patient News is North America’s most comprehensive and innovative dental marketing solutions provider. Founded in Canada in 1992, the company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom. The company has been named a Top 100 employer for four consecutive years, and has officially added environmental sustainability to its core values within the company vision.
Contact:

Click here to see all recent news from this company